1061 — Essex Bio-Technology Share News
0.000.00%
- HK$1.15bn
- HK$693.22m
- HK$1.81bn
Brief: Essex Bio-Technology Posts Profit For Year Of HK$302.5 Mln
HK-listed biopharma product maker Essex falls, says epidemic hit sales
Brief: Essex Bio-Technology Updates On Potential Impact Of Novel Coronavirus On Business Operations
Brief: Essex Bio-Technology Says NMPA Approved Registration & Commercialisation Of Single-Dose Beifushu Eye Drops In PRC
Brief: Essex Bio-Technology HY Profit For Period Hk$129.6 Million
Brief: Essex Bio-Technology Says Unit Agreed To Subscribe For Subscription Shares Of Antikor
Brief: Essex Bio-Technology Updates On U.S. FDA First Phase 3 Clinical Trial Relating To Dry Eye Disease
Brief: Essex Bio-Technology Posts Profit For Year Of HK$231.1 Million
Brief: Essex Bio-Technology Says Unit To Subscribe For Series Of Convertible Notes
Brief: Essex Bio-Technology Says Unit Obtained Approval From State Drug Administration For A Product
Brief: Essex Bio-Technology Posts Hy Profit For Period Of Hk$98.9 Mln
Brief: Essex Bio-Technology Says Unit to Make Investment In Chengdu Shanggong
Brief: Essex Bio-Technology Says Acquisition Of Land Use Rights And Construction Of Production Plant
Brief: Essex Bio-Technology's Unit Gets Approval For Commercialisation Of Eye Drops In China
Development Agreement
Brief: Essex Bio-Technology Says Unit To Invest RMB200 Mln In A Construction Project
Brief: Essex Bio-Technology Posts FY Profit Of HK$167.3 Mln
Brief: Essex bio-technology terminates proposed KDR programme
Brief: Essex Bio-Technology posts HY profit attributable of HK$77.1 mln